このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Royalty Pharma マネジメント

マネジメント基準チェック /34

Royalty Pharma'sの CEO はPablo Legorretaで、 Jan1996年に任命され、の在任期間は 28.42年です。は、会社の株式の0.81%を直接所有しており、その価値は$ 130.49M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4年です。

主要情報

Pablo Legorreta

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	28.4yrs
CEOの所有権	0.8%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	4yrs

経営陣の近況

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25

CEO報酬分析

Royalty Pharma の収益と比較して、Pablo Legorreta の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$799m
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	n/a	n/a	US$184m
Jun 30 2023	n/a	n/a	US$255m
Mar 31 2023	n/a	n/a	US$332m
Dec 31 2022	n/a	n/a	US$43m
Sep 30 2022	n/a	n/a	US$507m
Jun 30 2022	n/a	n/a	US$466m
Mar 31 2022	n/a	n/a	US$602m
Dec 31 2021	US$50m	US$8m	US$620m
Sep 30 2021	n/a	n/a	US$783m
Jun 30 2021	n/a	n/a	US$972m
Mar 31 2021	n/a	n/a	US$493m
Dec 31 2020	US$56m	n/a	US$495m
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$29m	n/a	US$2b

報酬と市場: Pabloの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Pabloの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Pablo Legorreta (60 yo)

28.4yrs

在職期間

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pablo Legorreta	Founder	28.4yrs	データなし	0.81% $ 129.0m
Terrance Coyne	Executive VP & CFO	no data	US$4.56m	0.19% $ 29.6m
George Lloyd	Executive VP of Investments & Chief Legal Officer	1.7yrs	US$4.56m	0.24% $ 37.9m
Christopher Hite	Vice Chairman & Executive VP	4.2yrs	US$4.56m	0.082% $ 13.0m
Marshall Urist	Executive Vice President of Research & Investments	3.5yrs	US$4.56m	0.015% $ 2.3m
Arthur McGivern	Executive Vice President of Investments & General Counsel	1.7yrs	データなし	データなし
Ashwin Pai	Executive Vice President of Investments	1.2yrs	データなし	データなし
Kristin Stafford	Senior VP & Chief Accounting Officer	no data	データなし	データなし
Eric Schneider	Senior VP & Chief Technology Officer	less than a year	データなし	データなし
James Reddoch	Executive VP of Investments & Chief Scientific Officer	3.5yrs	US$3.40m	0.19% $ 29.7m
George Grofik	Senior VP and Head of Investor Relations & Communications	no data	データなし	データなし
Alessandra Sassun	Senior VP & Head of Human Capital	2.5yrs	データなし	データなし

2.5yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: RPRXの経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Pablo Legorreta	Founder	28.4yrs	データなし	0.81% $ 129.0m
David Hodgson	Independent Director	2yrs	US$389.77k	0.0036% $ 577.1k
Ted Love	Independent Director	3.9yrs	US$389.77k	0.0082% $ 1.3m
Errol De Souza	Independent Director	4yrs	US$389.77k	0.014% $ 2.3m
Henry Fernandez	Lead Independent Director	3.9yrs	US$389.77k	0.022% $ 3.5m
Gregory Norden	Independent Director	4yrs	US$389.77k	0.014% $ 2.3m
Bonnie Bassler	Independent Director	4yrs	US$389.77k	0.011% $ 1.7m
Catherine Engelbert	Independent Director	4yrs	US$389.77k	0.0076% $ 1.2m

4.0yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: RPRXの取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

Royalty Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Recent updates

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.20 per share at 2.1% yield

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Consensus forecasts updated

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

Director recently sold US$2.5m worth of stock

Director recently sold US$16m worth of stock

Director notifies of intention to sell stock

Director recently sold US$5.1m worth of stock

Consensus forecasts updated

High number of new and inexperienced directors

マネジメント基準チェック /34